Particle.news
Download on the App Store
9 ARTICLES
·
6mo ago

Eli Lilly Expands Legal Fight Against Compounded GLP-1 Drugs

The pharmaceutical company has filed lawsuits against four telehealth providers, intensifying its campaign to halt unapproved versions of its diabetes and weight-loss medications.

The Empower Pharmacy facility maximizes the use of automation, utilizes equipment to generate purified water, clean steam and clean compressed air, and includes a large warehouse capable of storing at least nine months of raw pharmaceutical ingredients to minimize supply chain deficiencies that could interfere with patient care.
Image
The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February 1, 2018. REUTERS/Vincent Kessler/File photo
Empower Pharmacy hosts a celebration for the reinvention and expansion of the company with a new outsourcing facility on Thursday, Sept. 29, 2016, in Houston.

Overview

  • Eli Lilly filed lawsuits on April 23, 2025, against four telehealth companies—Mochi Health, Fella & Delilah Health, Willow Health, and Henry Meds—alleging they sell mass-produced, compounded versions of its GLP-1 drugs with unapproved formulations.
  • The lawsuits follow Eli Lilly's earlier legal action against Houston-based Empower Pharmacy, which continues to compound tirzepatide products despite FDA warnings and an April 24 deadline to respond to the lawsuit.
  • The FDA declared the shortages of GLP-1 drugs like tirzepatide and semaglutide over in late 2024, setting deadlines for compounders to cease production, though some continue to sell modified versions of the drugs.
  • Eli Lilly argues that these compounded drugs, often marketed as personalized, are instead mass-produced with untested additives, posing potential safety risks to patients.
  • The legal battle underscores tensions between pharmaceutical companies, compounding pharmacies, and telehealth providers over patient safety, affordability, and access to high-demand diabetes and weight-loss treatments.